Description: CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
Home Page: www.cormedix.com
300 Connell Drive
Berkeley Heights,
NJ
07922
United States
Phone:
908 517 9500
Officers
| Name | Title |
|---|---|
| Mr. Joseph Todisco MBA | CEO & Director |
| Dr. Matthew T. David M.D. | Executive VP & CFO |
| Ms. Erin Mistry | Executive VP & Chief Commercial Officer |
| Ms. Elizabeth Masson-Hurlburt B.A. | Executive VP and Chief Clinical Strategy & Operations Officer |
| Ms. Kaufman Beth Zelnick Esq. | Executive VP, Chief Legal Officer & Corporate Secretary |
| Donna Ucci | Senior VP & Head of Global Quality |
| Dr. Tushar Mukherjee | Senior VP & Head of Technical Operations |
Exchange: F
Country: DE : Germany
Currency: Euro (€)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 36.63 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 9.8456 |
| Price-to-Sales TTM: | 45.6605 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 82 |